As of November 6, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of Avalyn Pharma Inc. The largest reported stake is Fmr LLC's, at 13.2%. 7 filings are on record since May 5, 2026 (Schedule 13G/A, August 6, 2026).
Sell to companies like Avalyn Pharma Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Novo Holdings A/S · Sole voting: 3,883,289 · Shared voting: 0 · Sole dispositive: 3,883,289 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-14
- · Reporting person: Norwest Venture Partners XV, LP · Sole voting: 0 · Shared voting: 2,268,404 · Sole dispositive: 0 · Shared dispositive: 2,268,404 · SCHEDULE 13G, 2026-08-11
- · Reporting person: Fmr LLC · Sole voting: 5,762,944 · Shared voting: 0 · Sole dispositive: 5,835,259 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-06
- · Holder: Suvretta Capital Management, LLC · Percent: 5.6% · SCHEDULE 13D
- · Holder: SR One Capital Management, LLC · Percent: 7.5% · SCHEDULE 13D
Avalyn Pharma Inc. has 7 Schedule 13D or 13G filings on record since 2026-05-05. 6 holders' latest filing reports 5% or more of voting common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Fmr LLC | 13.2% | 5,835,259 | SCHEDULE 13G/A, 2026-08-06 | 2026-06-30 |
| Novo Holdings A/S | 8.8% | 3,883,289 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| SR One Capital Management, LLC | 7.5% | 3,308,649 | SCHEDULE 13D, 2026-05-08 | 2026-05-01 |
| Perceptive Advisors LLC | 6% | 2,675,296 | SCHEDULE 13G, 2026-05-07 | 2026-04-30 |
| Suvretta Capital Management, LLC | 5.6% | 2,503,109 | SCHEDULE 13D, 2026-05-08 | 2026-05-01 |
| Norwest Venture Partners XV, LP | 5.1% | 2,268,404 | SCHEDULE 13G, 2026-08-11 | 2026-06-30 |
Holding shares or following this stake? See who's behind Avalyn Pharma Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Avalyn Pharma Inc. and the records around it.
Avalyn Pharma Inc. elsewhere on the record
Companies that share a holder
- SR One Capital Management, LLC also filed stake reports on 6 other companies: ADARx Pharmaceuticals, Inc. (Oct 2026), Zenas BioPharma, Inc. (Aug 2026), Veradermics, Inc. (Aug 2026)
- Novo Holdings A/S also filed stake reports on 11 other companies: Hemab Therapeutics Holdings, Inc. (Aug 2026), Obsidian Therapeutics, Inc. (Aug 2026), MAPLIGHT THERAPEUTICS, INC. (Jul 2026)
- SUVRETTA CAPITAL MANAGEMENT, LLC also filed stake reports on 22 other companies: Veradermics, Inc (Aug 2026), Abeona Therapeutics Inc. (Aug 2026), Fulcrum Therapeutics, Inc. (Aug 2026)
Watch Avalyn Pharma Inc.
Get an email when Avalyn Pharma Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Avalyn Pharma Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Avalyn Pharma Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Avalyn Pharma Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Fmr LLC | 5,762,944 | 0 | 5,835,259 | 0 | SCHEDULE 13G/A, 2026-08-06 |
| Abigail P. Johnson | 0 | 0 | 5,835,259 | 0 | SCHEDULE 13G/A, 2026-08-06 |
| Novo Holdings A/S | 3,883,289 | 0 | 3,883,289 | 0 | SCHEDULE 13G, 2026-08-14 |
| Norwest Venture Partners XV, LP | 0 | 2,268,404 | 0 | 2,268,404 | SCHEDULE 13G, 2026-08-11 |
| Genesis VC Partners XV, LLC | 0 | 2,268,404 | 0 | 2,268,404 | SCHEDULE 13G, 2026-08-11 |
| NVP Associates, LLC | 0 | 2,268,404 | 0 | 2,268,404 | SCHEDULE 13G, 2026-08-11 |
| Jeffrey Crowe | 0 | 2,268,404 | 0 | 2,268,404 | SCHEDULE 13G, 2026-08-11 |
| Jon Erik Kossow | 0 | 2,268,404 | 0 | 2,268,404 | SCHEDULE 13G, 2026-08-11 |
The latest filing identifies Avalyn Pharma Inc. by CUSIP 05348Y105 and gives its principal executive office as 105 W First Street, Boston, MA 02127 (SCHEDULE 13G, 2026-08-14).
What the percentages are based on
Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2026 and is incorporated by reference.Norwest Venture Partners XV, LP, SCHEDULE 13G, 2026-08-11
Purpose of Transaction (Item 4)
Suvretta Capital Management, LLC
The disclosure in Item 3 above is incorporated herein by reference. The Funds hold securities of the Issuer for investment purposes. The Reporting Persons or their affiliates may purchase additional securities or dispose of securities in varying amounts and at varying times depending upon the Reporting Persons' continuing assessments of pertinent factors, including the availability of shares of Common Stock or other securities for purchase at particular price levels, the business prospects of the Issuer, other business investment opportunities, economic conditions, stock market conditions, the attitudes and actions of the board of directors of the Issuer (the "Board") and management of the Issuer, and the availability and nature of opportunities to dispose of securities of the Issuer. The Reporting Persons may discuss items of mutual interest with the Issuer's management, other members of the Board and other investors, which could include items in subparagraphs (a) through (j) of Item 4 Schedule 13D. Depending upon their assessments of the above factors, the Reporting Persons or their affiliates may change their present intentions as stated above and they may assess whether to make suggestions to the management of the Issuer regarding financing, and whether to acquire additional securities of the Issuer (by means of open market purchases, privately negotiated purchases, or otherwise) or to dispose of some or all of the securities of the Issuer under their control. …The first part of Item 4 of the SCHEDULE 13D filed 2026-05-08; the filing has the rest
SR One Capital Management, LLC
The Funds acquired their respective shares for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, the Funds and other Reporting Persons may dispose of or acquire additional shares of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer's business or corporate structure; (g) Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (h) Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a …The first part of Item 4 of the SCHEDULE 13D filed 2026-05-08; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-05-05 | Fmr LLC | 11.5% | SCHEDULE 13G |
| 2026-05-07 | Perceptive Advisors LLC | 6% | SCHEDULE 13G |
| 2026-05-08 | Suvretta Capital Management, LLC | 5.6% | SCHEDULE 13D |
| 2026-05-08 | SR One Capital Management, LLC | 7.5% | SCHEDULE 13D |
| 2026-08-06 | Fmr LLC | 13.2% | SCHEDULE 13G/A |
| 2026-08-11 | Norwest Venture Partners XV, LP | 5.1% | SCHEDULE 13G |
| 2026-08-14 | Novo Holdings A/S | 8.8% | SCHEDULE 13G |
Questions about who owns Avalyn Pharma Inc.
Who owns Avalyn Pharma Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Avalyn Pharma Inc.: Fmr LLC (13.2%, Schedule 13G/A, filed 2026-08-06), Novo Holdings A/S (8.8%, Schedule 13G, filed 2026-08-14), SR One Capital Management, LLC (7.5%, Schedule 13D, filed 2026-05-08), Perceptive Advisors LLC (6%, Schedule 13G, filed 2026-05-07) and Suvretta Capital Management, LLC (5.6%, Schedule 13D, filed 2026-05-08); 1 more is listed above.
Who are the largest shareholders of Avalyn Pharma Inc.?
By the share each holder's latest filing reports, the largest holders of Avalyn Pharma Inc. on this page are Fmr LLC (13.2%), Novo Holdings A/S (8.8%) and SR One Capital Management, LLC (7.5%).
When did Fmr LLC buy into Avalyn Pharma Inc.?
The filings give report dates, not purchase dates. The earliest filing from Fmr LLC on this page is the Schedule 13G, filed 2026-05-05, reporting 11.5%; its latest, Schedule 13G/A filed 2026-08-06, reports 13.2%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Avalyn Pharma Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 16, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| April 30, 2026 | IPO filing, Form 424B4 | $18 a share | IPO filings | Source |
| April 29, 2026 | IPO filing, Form S-1/A | — | IPO filings | Source |
| April 23, 2026 | IPO filing, Form S-1/A | — | IPO filings | Source |
| April 8, 2026 | IPO filing, Form S-1 | — | IPO filings | Source |
Tools for this story
Each opens in a new tab, filled in for Avalyn Pharma Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.